文献速递呼吸衰竭与机械通气心脑血管急症重症综合管理与镇静镇痛

COVID-19合并肺栓塞:临床特征与心脏表现

Pulmonary embolism in COVID-19: Clinical characteristics and cardiac implications.
PubMed 文献 · Am J Emerg Med · 2020-07-24
一句话结论COVID-19病程迁延、症状不缓解、呼吸困难加重、持续需氧或D-二聚体显著升高者应排查肺栓塞,TTE和ECG不可靠。

单中心回顾性观察队列纳入2020年3月1日至4月30日住院的COVID-19患者,经CTPA确诊肺栓塞15例(中位年龄58岁,87%男性)。最常见症状为呼吸困难(67%)和发热(47%),80%入院前症状持续≥7天不缓解;47%需CPAP,其中13%后续插管。所有患者D-二聚体、LDH、CRP、铁蛋白及凝血酶原时间均显著升高;93%为外周或亚段肺栓塞,仅1例中央型;67%静息ECG异常(最常见窦性心动过速),40%接受TTE者右心结构和功能正常。作者提示TTE和ECG在此背景下对肺栓塞预测不可靠。

要点

  • COVID-19患者急性恶化、病程迁延症状不缓解、呼吸困难加重或持续需氧时,应排查肺栓塞。
  • D-二聚体显著升高是重要提示,本队列所有确诊肺栓塞患者D-二聚体均显著升高。
  • 本队列93%(14/15)为外周或亚段肺栓塞,仅1例中央型,分布与CTPA实变模式相关(60%)。
  • TTE不可靠:40%(6/15)接受TTE者右心结构和功能正常;ECG仅67%异常,最常见为窦性心动过速。
  • 本队列病死率13%(2/15),均为>70岁男性。

适用人群与场景

  • 2020年3月1日至4月30日住院的COVID-19患者(单中心),后续经CTPA确诊肺栓塞。

诊断标准与关键阈值

  • 肺栓塞诊断依据:CTPA确诊。
  • 原文未提及D-二聚体具体界值或其他评分阈值。

处置流程与药物剂量

  • 原文未提及具体抗凝药物、剂量、给药途径或疗程。
  • 原文提及7例(47%)需CPAP,其中2例(13%)后续插管,但未给出具体参数或流程。

红旗征与不能漏的情况

  • 急性恶化、病程迁延伴症状不缓解、呼吸困难加重、持续需氧或D-二聚体显著升高者应排查肺栓塞(尤其COVID-19背景下)。
  • >70岁男性患者死亡2例(13%),需关注。

研究设计与关键结果

  • 单中心回顾性观察队列,15例COVID-19合并肺栓塞患者,中位年龄58岁(IQR 23),87%男性。
  • 症状:呼吸困难67%(10/15),发热47%(7/15);80%(12/15)入院前症状持续≥7天不缓解。
  • 呼吸支持:47%(7/15)需CPAP,其中13%(2/15)后续插管;病死率13%(2/15),均为>70岁男性。
  • 实验室:所有患者D-二聚体、LDH、CRP、铁蛋白及凝血酶原时间均显著升高。
  • 影像:93%(14/15)为外周或亚段肺栓塞,仅1例中央型;60%(9/15)肺栓塞分布与CTPA实变模式相关。
  • 心脏评估:67%(10/15)静息ECG异常,最常见窦性心动过速;40%(6/15)接受TTE者右心结构和功能正常。

证据类型、等级与局限

  • 证据类型:单中心、回顾性观察性队列研究(原文明确写 single centre, retrospective observational cohort study)。
  • 局限性:原文未述局限性。

对床旁实践的改变

  • 对COVID-19患者出现急性恶化、症状迁延不缓解、呼吸困难加重、持续需氧或D-二聚体显著升高时,应考虑行CTPA排查肺栓塞。
  • 本队列以周围型/亚段肺栓塞为主(93%),阅读CTPA时需注意外周及亚段分支。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: The thrombogenic potential of Covid-19 is increasingly recognised. We aim to assess the characteristics of COVID-19 patients diagnosed with pulmonary embolism (PE).

METHODS: We conducted a single centre, retrospective observational cohort study of COVID-19 patients admitted between 1st March and 30th April 2020 subsequently diagnosed with PE following computed tomography pulmonary angiogram (CTPA). Patient demographics, comorbidities, presenting complaints and inpatient investigations were recorded.

RESULTS: We identified 15 COVID-19 patients diagnosed with PE (median age = 58 years [IQR = 23], 87% male). 2 died (13%), both male patients >70 years. Most common symptoms were dyspnoea (N = 10, 67%) and fever (N = 7, 47%). 12 (80%) reported 7 days or more of non-resolving symptoms prior to admission. 7 (47%) required continuous positive airway pressure (CPAP), 2 (13%) of which were subsequently intubated. All patients had significantly raised D-dimer levels, lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin and prothrombin times. The distribution of PEs correlated with the pattern of consolidation observed on CTPA in 9 (60%) patients; the majority being peripheral or subsegmental (N = 14, 93%) and only 1 central PE. 10 (67%) had an abnormal resting electrocardiogram (ECG), the commonest finding being sinus tachycardia. 6 (40%) who underwent transthoracic echocardiography (TTE) had structurally and functionally normal right hearts.

CONCLUSION: Our study suggests that patients who demonstrate acute deterioration, a protracted course of illness with non-resolving symptoms, worsening dyspnoea, persistent oxygen requirements or significantly raised D-dimer levels should be investigated for PE, particularly in the context of COVID-19 infection. TTE and to a lesser degree the ECG are unreliable predictors of PE within this context.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Kho J, Ioannou A, Van den Abbeele K, et al. Pulmonary embolism in COVID-19: Clinical characteristics and cardiac implications. Am J Emerg Med. 2020. PMID: 33046316. doi:10.1016/j.ajem.2020.07.054

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。